JP2022518504A5 - - Google Patents

Info

Publication number
JP2022518504A5
JP2022518504A5 JP2021542384A JP2021542384A JP2022518504A5 JP 2022518504 A5 JP2022518504 A5 JP 2022518504A5 JP 2021542384 A JP2021542384 A JP 2021542384A JP 2021542384 A JP2021542384 A JP 2021542384A JP 2022518504 A5 JP2022518504 A5 JP 2022518504A5
Authority
JP
Japan
Prior art keywords
item
inhibitor
composition according
itrs
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021542384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518504A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/015026 external-priority patent/WO2020154645A1/en
Publication of JP2022518504A publication Critical patent/JP2022518504A/ja
Publication of JP2022518504A5 publication Critical patent/JP2022518504A5/ja
Pending legal-status Critical Current

Links

JP2021542384A 2019-01-24 2020-01-24 閉端dna(cedna)ならびに遺伝子療法または核酸療法に関連する免疫応答を低減させる方法における使用 Pending JP2022518504A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201962796417P 2019-01-24 2019-01-24
US201962796450P 2019-01-24 2019-01-24
US62/796,450 2019-01-24
US62/796,417 2019-01-24
US201962800285P 2019-02-01 2019-02-01
US201962800303P 2019-02-01 2019-02-01
US62/800,285 2019-02-01
US62/800,303 2019-02-01
US201962814414P 2019-03-06 2019-03-06
US201962814424P 2019-03-06 2019-03-06
US62/814,414 2019-03-06
US62/814,424 2019-03-06
US201962857542P 2019-06-05 2019-06-05
US62/857,542 2019-06-05
PCT/US2020/015026 WO2020154645A1 (en) 2019-01-24 2020-01-24 Close-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune response

Publications (2)

Publication Number Publication Date
JP2022518504A JP2022518504A (ja) 2022-03-15
JP2022518504A5 true JP2022518504A5 (cg-RX-API-DMAC7.html) 2023-02-02

Family

ID=71735812

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021542384A Pending JP2022518504A (ja) 2019-01-24 2020-01-24 閉端dna(cedna)ならびに遺伝子療法または核酸療法に関連する免疫応答を低減させる方法における使用

Country Status (11)

Country Link
US (1) US20220119840A1 (cg-RX-API-DMAC7.html)
EP (1) EP3914717A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022518504A (cg-RX-API-DMAC7.html)
KR (1) KR20210119416A (cg-RX-API-DMAC7.html)
CN (1) CN113412331A (cg-RX-API-DMAC7.html)
AU (1) AU2020211457A1 (cg-RX-API-DMAC7.html)
CA (1) CA3127799A1 (cg-RX-API-DMAC7.html)
MA (1) MA54826A (cg-RX-API-DMAC7.html)
MX (1) MX2021008874A (cg-RX-API-DMAC7.html)
SG (1) SG11202107922QA (cg-RX-API-DMAC7.html)
WO (1) WO2020154645A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
JP2021511047A (ja) * 2018-01-19 2021-05-06 ジェネレーション バイオ カンパニー 無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス
CN108920903B (zh) * 2018-07-09 2022-04-01 湘潭大学 基于朴素贝叶斯的LncRNA与疾病的关联关系预测方法及系统
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
US20220175816A1 (en) * 2019-04-18 2022-06-09 University Of Massachusetts Aim2 inhibitors and uses thereof
US20210371465A1 (en) * 2020-03-26 2021-12-02 Yale University Method of using a tlr9 antagonist as an anti-inflammatory and anti-fibrotic agent
MX2023001109A (es) 2020-07-27 2023-04-24 Anjarium Biosciences Ag Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
AU2021330936A1 (en) * 2020-08-23 2023-05-04 Bioverativ Therapeutics Inc. MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA)
CN112138164B (zh) * 2020-09-25 2022-06-03 徐州医科大学 Aim2在制备降低car-t治疗毒副作用的药物中的应用
WO2022182792A1 (en) 2021-02-23 2022-09-01 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
IL306038A (en) * 2021-03-22 2023-11-01 Massachusetts Inst Technology Multicellular microRNA sensing with elemental erns to regulate multipolar gene expression in mammalian cells
JP2024540994A (ja) * 2021-07-23 2024-11-06 スパーク セラピューティクス インコーポレイテッド 非ウイルス性dna送達のための方法および組成物
AU2022211795A1 (en) * 2021-08-06 2023-02-23 Syte.Bio Inc. Hairpin loop ended self-complementary double-stranded covalently closed linear dna vector, manufacturing system and process, and uses of said resulting dna vector
EP4396349A4 (en) * 2021-09-02 2025-10-22 Molecular Axiom Llc COMPOSITIONS AND METHODS FOR MODULATING NLRP3 OR NLRP1 EXPRESSION
CN114796216A (zh) * 2022-01-04 2022-07-29 南京医科大学 甲氟喹在防治全身代谢性炎症疾病中的应用
JP2025532680A (ja) * 2022-09-20 2025-10-01 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 抗線維化マイクロrna組成物
WO2024121814A1 (en) 2022-12-09 2024-06-13 Takeda Pharmaceutical Company Limited Modified immunomodulators
KR20250155027A (ko) 2023-02-21 2025-10-29 포세이다 테라퓨틱스, 인크. Aav piggybac 트랜스포존 폴리뉴클레오티드 조성물 및 이의 사용 방법
CN121532216A (zh) * 2023-04-18 2026-02-13 赛仁生物技术公司 腺相关病毒载体组合物和使用方法
IL327036A (en) 2023-09-19 2026-05-01 Poseida Therapeutics Inc Compositions and methods for combining viral vectors
CN122341729A (zh) * 2023-11-30 2026-07-03 赛诺菲 末端封闭的dna分子的纯化

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377898B2 (en) * 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
EP2500434A1 (en) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
WO2013019623A2 (en) * 2011-07-29 2013-02-07 Fred Hutchinson Cancer Research Center Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject
AU2015342968B2 (en) * 2014-11-05 2021-05-27 Selecta Biosciences, Inc. Methods and compositions related to the use of low HLB surfactants in the production of synthetic nanocarriers comprising a rapalog
IL261524B2 (en) * 2016-03-03 2023-10-01 Univ Massachusetts End-capped linear double-stranded DNA for non-viral gene transfer
EP3468605A4 (en) * 2016-06-08 2020-01-08 President and Fellows of Harvard College MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS

Similar Documents

Publication Publication Date Title
JP7504967B2 (ja) MeCP2発現カセット
EP3702466B1 (en) Products and methods for treatment of amyotrophic lateral sclerosis
KR102931619B1 (ko) 알파-시뉴클레인에 대한 변이형 RNAi
JP2022046792A (ja) 組織特異的発現のための改変u6プロモーターシステム
JP7541027B2 (ja) 筋肉発現のためのハイブリッドプロモーター
JP2021534755A (ja) 筋強直性ジストロフィープロテインキナーゼの発現を抑制および/またはdmpk遺伝子の3’非翻訳領域におけるトリヌクレオチドリピート伸長に干渉するための組換えウイルス産物および方法
EP3495472A1 (en) Recombinant virus products and methods for inhibition of expression of myotilin
JP2026500351A (ja) 心筋および骨格筋特異的標的化モチーフを有する組換えaav変異体ベクターおよびそれを含む組成物
EP3613856A1 (en) Shrna expression cassette, polynucleotide sequence carrying same, and application thereof
US20230044220A1 (en) Treatment of chronic pain
JPWO2019156115A1 (ja) オリゴデンドロサイト特異的プロモータ、PLP1遺伝子に特異的なmiRNA、該プロモータ及び/又は該miRNAを含むベクター並びに該ベクターを含む医薬組成物
EP4603585A1 (en) Snrna nucleic acid molecule and application thereof
AU2022282057B2 (en) Novel dual helper plasmid
US20240392291A1 (en) Nucleotide and use thereof
WO2011111072A2 (en) Adeno-associated virus ezh2 shrna (aav ezh2 shrna)therapy for breast cancer
JP2025509262A5 (cg-RX-API-DMAC7.html)
JP2025512709A5 (cg-RX-API-DMAC7.html)
JP2022523320A5 (cg-RX-API-DMAC7.html)
CA3219287C (en) Dual helper plasmid
RU2788605C2 (ru) ОЛИГОДЕНДРОЦИТ-СПЕЦИФИЧНЫЙ ПРОМОТОР, микроРНК, СПЕЦИФИЧНАЯ К ГЕНУ PLP1, ВЕКТОР, СОДЕРЖАЩИЙ УКАЗАННЫЙ ПРОМОТОР И/ИЛИ УКАЗАННУЮ микроРНК, И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ УКАЗАННЫЙ ВЕКТОР
WO2023240177A1 (en) Products and methods for treating diseases or conditions associated with mutant or pathogenic kcnq3 expression
HK40031811B (en) Products and methods for treatment of amyotrophic lateral sclerosis
Lai et al. 1063. Optimizing Intron Splicing Signal Overcomes the mRNA Accumulation Barrier in Trans-Splicing AAV Vectors.
RU2021122081A (ru) ДНК С ЗАМКНУТЫМИ КОНЦАМИ (зкДНК) И ПРИМЕНЕНИЕ В СПОСОБАХ УМЕНЬШЕНИЯ ИММУННОГО ОТВЕТА, СВЯЗАННОГО С ГЕННОЙ ТЕРАПИЕЙ ИЛИ ТЕРАПИЕЙ НУКЛЕИНОВОЙ КИСЛОТОЙ
HK40009865A (en) Recombinant virus products and methods for inhibition of expression of myotilin